A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis

Inhaled amphotericin, a antifungal drug would decrease Aspergillus colonization and decrease the occurrence of exacerbations of Allergic Bronchopulmonary Aspergillosis (ABPA).

 

Condition Intervention Phase
Allergic Bronchopulmonary Aspergillosis Drug: Inhaled budesonide
Drug: Inhaled amphotericin		 Phase 2
Phase 3

 
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Date of article/Start date of trial: 13 May 2013

Trial Phase: Phase 3

clinical Trials Gov ID: NCT01857479

Trial status: Completed

Back to New Antifungals